Veraxa Biotech AG - Post de-SPAC (NASDAQ:VRXA)
| Market Cap | $147.06M-91.5% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 141.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,628 |
| Open | $1.03 |
| Previous Close | $1.03 |
| Day's Range | $1.03 - $1.06 |
| 52-Week Range | $0.90 - $27.36 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VRXA
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Veraxa Biotech AG - Post de-SPAC Stock Analysis — InsiderScore
Veraxa Biotech AG - Post de-SPAC scored higher than 88% of companies evaluated by InsiderBuying, and ranked 10th out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Veraxa Biotech AG - Post de-SPAC bought $125.3K of stock across 5 purchases in the last 90 days, the largest of them $75.0K.
The average purchase added about 89% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
2 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VRXA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VRXA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VRXA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VRXA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VRXA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VRXA from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from VRXA’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+24.2 since Sep 23Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
